Preventive treatment for hemophilia A in infants and children
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is under 12 years old, or 12–17 years old and weighs less than 40 kg.
- Has severe or moderate hemophilia A (with or without inhibitors), or mild hemophilia A with chronic inhibitors.
- Has a history of bleeding problems, like joint bleeds or spontaneous bleeds.
- If not on preventive treatment, agrees to switch to the study drug for prevention.
- Has adequate liver, kidney, and blood function and no other serious medical conditions.
- No planned major surgery during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This study tests a new medicine called NXT007 for people with moderate or severe hemophilia A. The goal is to see if it is safe, well-tolerated, and can help prevent or reduce bleeding episodes, possibly reducing the need for standard treatments. You may be able to join if you have hemophilia A with or without inhibitors and meet other health requirements.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This study tests a new medicine called SR604, given as a shot under the skin, to help prevent bleeding in people with hemophilia A or B. If it works, it could reduce the number of bleeding episodes and make daily life easier.
This study looks at why the body sometimes stops responding to factor VIII treatment in hemophilia A. It aims to find patterns that help doctors predict and manage this, so they can keep the treatment working well.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.